EpiAxis CEO Dr Jeremy Chrisp recently presented at Wholesale Investor’s Venture and Capital 2023, an exclusive conference designed to empower high-net-worth VCs, family offices and professional investors with access to investment opportunities and networking.
Venture & Capital Singapore was held on 31 August 2023 at Marina Bay Sands Expo & Convention Centre.
EpiAxis featured in an exclusive showcase of innovative companies, with Dr Chrisp providing an update on its disruptive epigenetic approach to overcome treatment resistance and prevent cancer recurrence.
The company recently nominated epiresatide as its lead candidate for IND advancement.
Epiresatide is a generation 2.1 stapled peptide specifically targeting nuclear LSD1, which offers a novel mode of action. Designed to address the challenge of treatment resistance and prevention of cancer recurrence in numerous haematological and solid tumours, epiresatide has demonstrated superior biological performance in modulating LSD1 demethylase activities, coupled with an excellent pre-clinical safety and tolerability profile.
“This is a pivotal valuation inflection point for shareholders and provides momentum for EpiAxis’ fundraising and partnering activities,” Dr Chrisp said.
“Currently, EpiAxis is actively seeking collaborations and investment opportunities to accelerate the development and commercialisation of epiresatide, cementing its position at the forefront of the biotechnology industry.”
For further inquiries, please contact:
Phone: +61 421 012 268
j.chrisp@epiaxistherapeutics.com
Learn more about Venture & Capital Singapore here.
Watch Dr Chrisp’s presentation below: